These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 38813084)

  • 1. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy.
    Basar OY; Mohammed S; Qoronfleh MW; Acar A
    Front Cell Dev Biol; 2024; 12():1369597. PubMed ID: 38813084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy in non-small cell lung cancer.
    Shu Y; Weng S; Zheng S
    Oncol Lett; 2020 Dec; 20(6):307. PubMed ID: 33093916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor endothelial cells as a potential target of metronomic chemotherapy.
    Kim JY; Kim YM
    Arch Pharm Res; 2019 Jan; 42(1):1-13. PubMed ID: 30604201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic Chemotherapy for Metastatic Breast Cancer.
    Krajnak S; Battista MJ; Hasenburg A; Schmidt M
    Oncol Res Treat; 2022; 45(1-2):12-17. PubMed ID: 34794154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy.
    Maharjan R; Choi JU; Kweon S; Pangeni R; Lee NK; Park SJ; Chang KY; Park JW; Byun Y
    Biomaterials; 2022 Feb; 281():121334. PubMed ID: 34974206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic Chemotherapy in Elderly Patients.
    Bandini A; Calabrò PF; Banchi M; Orlandi P; Bocci G
    Curr Oncol Rep; 2024 Apr; 26(4):359-376. PubMed ID: 38448722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
    Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
    J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
    Kareva I; Waxman DJ; Lakka Klement G
    Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.
    Jan N; Sofi S; Qayoom H; Shabir A; Haq BU; Macha MA; Almilaibary A; Mir MA
    Heliyon; 2024 Feb; 10(3):e24670. PubMed ID: 38314272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy.
    Maharjan R; Pangeni R; Jha SK; Choi JU; Chang KY; Choi YK; Park JW; Byun Y
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31337061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives.
    Panthi VK; Dua K; Singh SK; Gupta G; Hansbro PM; Paudel KR
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
    Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
    Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
    Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
    Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
    Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
    Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current achievements and future perspectives of metronomic chemotherapy.
    Romiti A; Falcone R; Roberto M; Marchetti P
    Invest New Drugs; 2017 Jun; 35(3):359-374. PubMed ID: 27909934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.